Form 4: Axsome CEO Sells Shares After Option Exercise

Axsome Therapeutics CEO Herriot Tabuteau executed planned sales of common stock following the exercise of expiring stock options in mid-September 2025.

Summary

• Herriot Tabuteau, CEO, Director, and 10% Owner of Axsome Therapeutics, Inc. (AXSM), engaged in a series of transactions involving the company's common stock.
• Transactions occurred on September 12, 15, and 16, 2025.
• These transactions were conducted pursuant to a pre-approved Rule 10b5-1 plan.
• The stock option exercises were necessary due to the options reaching their 10-year expiration date within the next year.
• On September 12, 2025, 27,907 shares were acquired via option exercise at $8.02 per share and subsequently sold at a weighted average price of $118.96 per share.
• On September 15, 2025, 15,254 shares were acquired via option exercise at $8.02 per share and subsequently sold at a weighted average price of $117.37 per share.
• On September 16, 2025, 19,719 shares were acquired via option exercise at $8.02 per share and subsequently sold at a weighted average price of $114.19 per share.
• Following these transactions, Herriot Tabuteau directly holds 7,229 shares of common stock and indirectly holds 7,344,500 shares through an entity where he has voting and dispositive power.
• The number of beneficially owned derivative securities (stock options) decreased from 496,093 to 461,120 after these exercises.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While insider selling can sometimes be a concern, these transactions were pre-planned under a 10b5-1 plan and driven by the impending expiration of stock options, which is a routine event. The high sale prices relative to the exercise price indicate significant value realization for the CEO, and the CEO retains substantial indirect ownership.

Positives

• The reporting person realized significant gains by selling shares at prices substantially higher than the exercise price ($8.02 vs. $114.19 $118.96).
• The transactions were executed under a pre-approved 10b5-1 plan, indicating a structured and pre-determined approach rather than opportunistic selling.
• The exercise of options was due to their impending expiration, which is a common and often necessary action for executives to realize value from their compensation.

Negatives

• The sale of a significant number of shares by a key insider (CEO, Director, 10% Owner) could be perceived negatively by some investors, despite the pre-planned nature and reason for the sale.
• The direct beneficial ownership of common stock decreased to 7,229 shares, although substantial indirect ownership remains.

Future Outlook

The transactions reflect a pre-planned execution strategy for expiring stock options, rather than a change in the company's operational outlook. The remaining stock options held by the CEO have an expiration date of May 27, 2026.

Management Comments

• The exercise of stock options was necessary due to the attainment of the 10-year expiration date of such options within the next year.
• All reported transactions were executed pursuant to a pre-approved 10b5-1 plan.
• The reporting person is deemed to be the indirect beneficial owner of 7,344,500 shares held by an entity where they have voting and dispositive power.

Industry Context

Insider transactions, particularly those involving the exercise of expiring options and subsequent sales, are a routine part of executive compensation and wealth management across all industries, including the biotechnology sector. The use of a 10b5-1 plan is a standard practice to mitigate concerns about insider trading by pre-scheduling transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the CEO's sale of shares with mixed feelings; some may see it as a natural part of compensation, while others might interpret it as a lack of confidence, despite the 10b5-1 plan and option expiry explanation. The significant indirect ownership might mitigate negative perceptions.
• Management/Employees: The CEO's ability to realize substantial value from stock options can be seen as a positive for executive compensation structures.

Next Steps

• The remaining stock options held by the CEO will expire on May 27, 2026.

Key Dates

Recommendation

While the CEO's sale of shares might typically raise concerns, these transactions were pre-planned under a 10b5-1 plan and driven by the impending expiration of stock options, which is a common and necessary action for executives. The CEO still retains a substantial indirect stake in the company. This Form 4 primarily reflects a routine compensation event rather than a fundamental shift in the company's prospects, thus a 'hold' recommendation is appropriate, pending further operational or financial updates from Axsome Therapeutics.

Keywords

Axsome Therapeutics, AXSM, Herriot Tabuteau, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO, Beneficial Ownership